Doctors test drug to prevent cancer in high risk womenBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7418.768 (Published 02 October 2003) Cite this as: BMJ 2003;327:768
- Zosia Kmietowicz
A drug that outperforms tamoxifen in the treatment of breast cancer is being investigated for its potential benefits in preventing the disease in women at high risk.
Anastrozole has already been shown to reduce the recurrence of breast cancer by 70%, some 25% more than tamoxifen. If it proves equally effective in preventing first time occurrence of breast cancer, experts say, anastrozole could drastically reduce the incidence of hormone sensitive breast cancers around the world. About 70% of the 30 000 breast cancers that occur in postmenopausal women in the United Kingdom each year are hormone sensitive.
The second international breast cancer intervention study (IBIS …
Log in using your username and password
Log in through your institution
Sign up for a free trial